Evolution of iPSC disease models

References

[1] Batista, L.F., Pech, M.F., Zhong, F.L., Nguyen, H.N., Xie, K.T., Zaug, A.J., Crary, S.M., Choi, J., Sebastiano, V., Cherry, A., (2011). Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature 474, 399-402 21602826.
[2] Bock, C., Kiskinis, E., Verstappen, G., Gu, H., Boulting, G., Smith, Z.D., Ziller, M., Croft, G.F., Amoroso, M.W., Oakley, D.H., (2011). Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 144, 439-452 21295703.
[3] Brennand, K.J., Simone, A., Jou, J., Gelboin-Burkhart, C., Tran, N., Sangar, S., Li, Y., Mu, Y., Chen, G., Yu, D., (2011). Modelling schizophrenia using human induced pluripotent stem cells. Nature 473, 221-225 21490598.
[4] Buchholz, D.E., Hikita, S.T., Rowland, T.J., Friedrich, A.M., Hinman, C.R., Johnson, L.V., and Clegg, D.O. (2009). Derivation of functional retinal pigmented epithelium from induced pluripotent stem cells. Stem Cells 27, 2427-2434 19658190.
[5] Devine, M.J., Ryten, M., Vodicka, P., Thomson, A.J., Burdon, T., Houlden, H., Cavaleri, F., Nagano, M., Drummond, N.J., Taanman, J.W., (2011). Parkinson’s disease induced pluripotent stem cells with triplication of the a-synuclein locus. Nat Commun 2, 44021863007.
[6] Deyle, D.R., Khan, I.F., Ren, G., Wang, P.-R., Kho, J., Schwarze, U., and Russell, D.W. (2011). Normal Collagen and Bone Production by Gene-targeted Human Osteogenesis Imperfecta iPSCs. Mol Ther Mol Ther 2011Oct 25.10.1038/mt.2011.209 [Epub ahead of print]
[7] Hockemeyer, D., Wang, H., Kiani, S., Lai, C.S., Gao, Q., Cassady, J.P., Cost, G.J., Zhang, L., Santiago, Y., Miller, J.C., (2011). Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 29, 731-734 21738127.
[8] Howden, S.E., Gore, A., Li, Z., Fung, H.L., Nisler, B.S., Nie, J., Chen, G., McIntosh, B.E., Gulbranson, D.R., Diol, N.R., (2011a). Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy. Proc Natl Acad Sci U S A 108, 6537-6542 21464322.
[9] Howden, S.E., Gore, A., Li, Z., Fung, H.L., Nisler, B.S., Nie, J., Chen, G., McIntosh, B.E., Gulbranson, D.R., Diol, N.R., (2011b). Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy. Proc Natl Acad Sci U S A 108, 6537-6542 21464322.
[10] Itzhaki, I., Maizels, L., Huber, I., Zwi-Dantsis, L., Caspi, O., Winterstern, A., Feldman, O., Gepstein, A., Arbel, G., Hammerman, H., (2011). Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471, 225-229 21240260.
[11] Kim, K., Zhao, R., Doi, A., Ng, K., Unternaehrer, J., Cahan, P., Hongguang, H., Loh, Y.H., Aryee, M.J., Lensch, M.W., (2011). Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol 29, 1117-1119 .
[12] Koch, P., Breuer, P., Peitz, M., Jungverdorben, J., Kesavan, J., Poppe, D., Doerr, J., Ladewig, J., Mertens, J., Tüting, T., (2011). Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature 480, 543-546
[13] Li, M., Suzuki, K., Qu, J., Saini, P., Dubova, I., Yi, F., Lee, J., Sancho-Martinez, I., Liu, G.H., and Belmonte, J.C. (2011). Efficient correction of hemoglobinopathy-causing mutations by homologous recombination in integration-free patient iPSCs. Cell Res 21, 1740-1744 .
[14] Liu, G.H., Barkho, B.Z., Ruiz, S., Diep, D., Qu, J., Yang, S.L., Panopoulos, A.D., Suzuki, K., Kurian, L., Walsh, C., (2011a). Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 472, 221-225 21346760.
[15] Liu, G.H., Sancho-Martinez, I., and Belmonte, J.C. (2011b). Cut and Paste: restoring cellular function by gene correction. Cell Res 2011Dec 6.10.1038/cr.2011.192. [Epub ahead of print]
[16] Liu, G.H., Suzuki, K., Qu, J., Sancho-Martinez, I., Yi, F., Li, M., Kumar, S., Nivet, E., Kim, J., Soligalla, R.D., (2011c). Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. Cell Stem Cell 8, 688-694 21596650.
[17] Marchetto, M.C., Carromeu, C., Acab, A., Yu, D., Yeo, G.W., Mu, Y., Chen, G., Gage, F.H., and Muotri, A.R. (2010). A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143, 527-539 21074045.
[18] Mazzulli, J.R., Xu, Y.H., Sun, Y., Knight, A.L., McLean, P.J., Caldwell, G.A., Sidransky, E., Grabowski, G.A., and Krainc, D. (2011). Gaucher disease glucocerebrosidase and a-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37-52 21700325.
[19] Nguyen, H.N., Byers, B., Cord, B., Shcheglovitov, A., Byrne, J., Gujar, P., Kee, K., Schüle, B., Dolmetsch, R.E., Langston, W., (2011). LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8, 267-280 21362567.
[20] Pan, H., Zhang, W., Zhang, W.Z., and Liu, G.H. (2011). Find and replace: editing human genome in pluripotent stem cells. Protein Cell 2, 950-956.
[21] Panopoulos, A.D., Ruiz, S., and Izpisua Belmonte, J.C. (2011). iPSCs: induced back to controversy. Cell Stem Cell 8, 347-348 21474093.
[22] Pa?ca, S.P., Portmann, T., Voineagu, I., Yazawa, M., Shcheglovitov, A., Pa?ca, A.M., Cord, B., Palmer, T.D., Chikahisa, S., Nishino, S., (2011). Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat Med 17, 1657-1662 22120178.
[23] Quarto, N., Leonard, B., Li, S., Marchand, M., Anderson, E., Behr, B., Francke, U., Reijo-Pera, R., Chiao, E., and Longaker, M.T. (2011). Skeletogenic phenotype of human Marfan embryonic stem cells faithfully phenocopied by patient-specific induced-pluripotent stem cells. Proc Natl Acad Sci U S A 2011Dec 16. [Epub ahead of print]
[24] Raya, A., Rodríguez-Pizà, I., Guenechea, G., Vassena, R., Navarro, S., Barrero, M.J., Consiglio, A., Castellà, M., Río, P., Sleep, E., (2009). Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 460, 53-59 19483674.
[25] Sebastiano, V., Maeder, M.L., Angstman, J.F., Haddad, B., Khayter, C., Yeo, D.T., Goodwin, M.J., Hawkins, J.S., Ramirez, C.L., Batista, L.F.Z., (2011). In Situ Genetic Correction of the Sickle Cell Anemia Mutation in Human Induced Pluripotent Stem Cells Using Engineered Zinc Finger Nucleases. Stem Cells 29,1717-1726 .
[26] Soldner, F., Laganière, J., Cheng, A.W., Hockemeyer, D., Gao, Q., Alagappan, R., Khurana, V., Golbe, L.I., Myers, R.H., Lindquist, S., (2011). Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146, 318-331 21757228.
[27] Tiscornia, G., Vivas, E.L., and Belmonte, J.C.I. (2011). Diseases in a dish: modeling human genetic disorders using induced pluripotent cells. Nat Med , 1570-1576 22146428.
[28] Urbach, A., Bar-Nur, O., Daley, G.Q., and Benvenisty, N. (2010). Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 6, 407-411 20452313.
[29] Wu, S.M., and Hochedlinger, K. (2011). Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol 13, 497-505 21540845.
[30] Yazawa, M., Hsueh, B., Jia, X., Pasca, A.M., Bernstein, J.A., Hallmayer, J., and Dolmetsch, R.E. (2011). Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471, 230-234 21307850.
[31] Yusa, K., Rashid, S.T., Strick-Marchand, H., Varela, I., Liu, P.-Q., Paschon, D.E., Miranda, E., Ordó?ez, A., Hannan, N.R.F., Rouhani, F.J., (2011). Targeted gene correction of a1-antitrypsin deficiency in induced pluripotent stem cells. Nature 478, 391-394 21993621.
[32] Zhang, J., Lian, Q., Zhu, G., Zhou, F., Sui, L., Tan, C., Mutalif, R.A., Navasankari, R., Zhang, Y., Tse, H.F., (2011). A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 8, 31-45 21185252.
[33] Zhao, T., Zhang, Z.N., Rong, Z., and Xu, Y. (2011). Immunogenicity of induced pluripotent stem cells. Nature 474, 212-215 .
[34] Zhu, H., Lensch, M.W., Cahan, P., and Daley, G.Q. (2011). Investigating monogenic and complex diseases with pluripotent stem cells. Nat Rev Genet 12, 266-275 21386866.
[35] Zou, J., Mali, P., Huang, X., Dowey, S.N., and Cheng, L. (2011). Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 118, 4599-4608 .